Q-omics provides the consensus-scored UBBP5 profile across patient tissues and cancer cell-line models. UBBP5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, UBBP5 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, UBBP5 RNA expression shows 8,295 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CHOL, KIRC, and ACC as cancer lineages where UBBP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBBP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBBP5 survival associations across molecular data types. UBBP5 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBBP5 RNA expression–survival associations across cancer types. High UBBP5 expression shows unfavorable associations in CHOL, HNSC, LIHC and UCS, but favorable associations in SKCM and CESC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for UBBP5 RNA expression.
This table summarizes UBBP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UBBP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBBP5 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, UCEC, BRCA and LIHC. The KIRC box plot shows higher UBBP5 RNA expression in tumor versus normal tissue (log2 FC = +0.868, t-test p < 0.001).
This table shows molecular features associated with UBBP5 in patient tissues and cancer cell lines. In patient samples, UBBP5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
